CN102869369B - 利用可溶性cd24治疗类风湿性关节炎的方法 - Google Patents

利用可溶性cd24治疗类风湿性关节炎的方法 Download PDF

Info

Publication number
CN102869369B
CN102869369B CN201180021423.6A CN201180021423A CN102869369B CN 102869369 B CN102869369 B CN 102869369B CN 201180021423 A CN201180021423 A CN 201180021423A CN 102869369 B CN102869369 B CN 102869369B
Authority
CN
China
Prior art keywords
hours
protein
minutes
mice
cd24fc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180021423.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102869369A (zh
Inventor
X.郑
W.吴
Y.刘
P.郑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncoimmune Inc
Original Assignee
Oncoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoimmune Inc filed Critical Oncoimmune Inc
Priority to CN201510683408.8A priority Critical patent/CN105381451B/zh
Publication of CN102869369A publication Critical patent/CN102869369A/zh
Application granted granted Critical
Publication of CN102869369B publication Critical patent/CN102869369B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201180021423.6A 2010-04-28 2011-04-28 利用可溶性cd24治疗类风湿性关节炎的方法 Expired - Fee Related CN102869369B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510683408.8A CN105381451B (zh) 2010-04-28 2011-04-28 利用可溶性cd24治疗类风湿性关节炎的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32907810P 2010-04-28 2010-04-28
US61/329,078 2010-04-28
PCT/US2011/034282 WO2011139820A1 (en) 2010-04-28 2011-04-28 Methods of use of soluble cd24 for therapy of rheumatoid arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510683408.8A Division CN105381451B (zh) 2010-04-28 2011-04-28 利用可溶性cd24治疗类风湿性关节炎的方法

Publications (2)

Publication Number Publication Date
CN102869369A CN102869369A (zh) 2013-01-09
CN102869369B true CN102869369B (zh) 2016-05-18

Family

ID=44903987

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180021423.6A Expired - Fee Related CN102869369B (zh) 2010-04-28 2011-04-28 利用可溶性cd24治疗类风湿性关节炎的方法
CN201510683408.8A Expired - Fee Related CN105381451B (zh) 2010-04-28 2011-04-28 利用可溶性cd24治疗类风湿性关节炎的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510683408.8A Expired - Fee Related CN105381451B (zh) 2010-04-28 2011-04-28 利用可溶性cd24治疗类风湿性关节炎的方法

Country Status (17)

Country Link
US (1) US8808697B2 (https=)
EP (3) EP3260128B1 (https=)
JP (5) JP5899206B2 (https=)
KR (1) KR20130086126A (https=)
CN (2) CN102869369B (https=)
AU (1) AU2011248540B2 (https=)
CA (1) CA2795823C (https=)
DK (1) DK2563385T3 (https=)
EA (2) EA036805B8 (https=)
ES (2) ES2826445T3 (https=)
IL (1) IL222739A0 (https=)
NO (1) NO2563385T3 (https=)
NZ (1) NZ603196A (https=)
PL (2) PL3260128T3 (https=)
PT (2) PT2563385T (https=)
SG (1) SG184907A1 (https=)
WO (1) WO2011139820A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
BR112017022394A2 (pt) * 2015-05-07 2018-07-17 Oncoimmune Inc uso de cd24 para diminuir níveis de colesterol das lipoproteínas de baixa densidade
KR20180120145A (ko) * 2016-02-02 2018-11-05 온코이뮨, 아이앤씨. 렙틴-결핍 병태를 치료하기 위한 cd24 단백질의 용도
US10758574B2 (en) 2016-04-28 2020-09-01 The Board Of Trustees Of The Leland Stanford Junior University Cartilage cells with a high regenerative potential and low immune response for use in cellular therapy
KR101789449B1 (ko) * 2016-12-08 2017-10-23 박문수 폐유지를 이용한 지방산 메틸에스테르 제조방법
WO2018165204A1 (en) * 2017-03-07 2018-09-13 Oncoimmune, Inc. Methods of use of soluble cd24 for treating systemic lupus erythematosus
US20200181235A1 (en) * 2017-05-15 2020-06-11 Oncoimmune, Inc. Methods of use of soluble cd24 for neuroprotection and remyelination
US11547741B2 (en) * 2017-05-22 2023-01-10 Oncoimmune, Inc. Methods of use of soluble CD24 for treating immune related adverse events in cancer therapies
JP2021523929A (ja) * 2018-03-05 2021-09-09 オンコイミューン， インコーポレイテッド 後天性免疫不全症候群（ｈｉｖ／ａｉｄｓ）の治療のための可溶性ｃｄ２４の使用方法
WO2019222082A1 (en) * 2018-05-14 2019-11-21 Oncoimmune, Inc. Anti-cd24 compositions and uses thereof
WO2019236474A1 (en) * 2018-06-04 2019-12-12 Oncoimmune, Inc. Methods of use of cd24 for the prevention and treatment of leukemia relapse
EP3870604B1 (en) 2018-10-26 2022-11-23 F. Hoffmann-La Roche AG Multispecific antibody screening method using recombinase mediated cassette exchange
AU2020336302A1 (en) * 2019-08-23 2022-03-03 Sana Biotechnology, Inc. CD24 expressing cells and uses thereof
CN112480237B (zh) * 2019-09-12 2023-10-17 上海津曼特生物科技有限公司 一种融合蛋白及其制备方法和应用
AU2021386254A1 (en) * 2020-11-30 2023-06-29 Blaze Bioscience, Inc. Compositions and methods for selective depletion of target molecules
EP4408862A4 (en) * 2021-09-28 2025-11-12 Acroimmune Guangzhou Biotech Ltd Fusion proteins including the O71 core peptide and their use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072325A1 (en) * 2000-03-29 2001-10-04 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive t cells
CN101254302A (zh) * 1999-05-07 2008-09-03 杰南技术公司 使用与b细胞表面标志结合的拮抗剂治疗自身免疫病

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5759775A (en) * 1994-10-27 1998-06-02 Genetech, Inc. Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
US20030095966A1 (en) * 2000-03-29 2003-05-22 Yang Liu Method of blocking tissue destruction by autoreactive T cells
US20030106084A1 (en) 2000-03-29 2003-06-05 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
US7189830B2 (en) * 2001-02-19 2007-03-13 Merck Patent Gmbh Anti-KSA/IL-2 fusion proteins with reduced immunogenicity
US20050214290A1 (en) * 2001-03-29 2005-09-29 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
HUP0400340A2 (hu) * 2001-07-13 2004-08-30 Merck Patent Gmbh. Polipeptidek immunogenitásának csökkentésére szolgáló eljárások
EP2292259A3 (en) 2002-11-15 2011-03-23 MUSC Foundation For Research Development Complement receptor 2 targeted complement modulators
EP2062916A3 (en) * 2003-04-09 2009-08-19 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor
AU2007242919B8 (en) * 2003-04-09 2011-11-10 F. Hoffmann-La Roche Ag Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
CA2549913A1 (en) * 2003-11-26 2005-06-16 The Ohio State University Research Foundation Polymorphic cd24 genotypes that are predictive of multiple sclerosis risk and progression
CA2567496A1 (en) * 2004-05-21 2005-12-01 Xencor, Inc. C1q family member proteins with altered immunogenicity
WO2006053245A2 (en) * 2004-11-12 2006-05-18 Iogenetics, Llc Retroviral vectors with introns

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101254302A (zh) * 1999-05-07 2008-09-03 杰南技术公司 使用与b细胞表面标志结合的拮抗剂治疗自身免疫病
WO2001072325A1 (en) * 2000-03-29 2001-10-04 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive t cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Investigating the role of CD24 gene polymorphisms in rheumatoid arthritis;Sanchez e et al;<Annals of the rheumatic diseases >;20080831;1197-1198 *

Also Published As

Publication number Publication date
KR20130086126A (ko) 2013-07-31
EA201290961A1 (ru) 2013-04-30
JP2018127493A (ja) 2018-08-16
EP2563385A4 (en) 2013-10-02
EP2563385A1 (en) 2013-03-06
HK1222554A1 (zh) 2017-07-07
JP2017057216A (ja) 2017-03-23
CN105381451A (zh) 2016-03-09
JP6062502B2 (ja) 2017-01-18
EA036805B1 (ru) 2020-12-23
CA2795823C (en) 2019-06-04
PL2563385T3 (pl) 2018-04-30
CA2795823A1 (en) 2011-11-10
ES2645262T3 (es) 2017-12-04
JP6888221B2 (ja) 2021-06-16
EA036805B8 (ru) 2021-02-25
EP3260128A1 (en) 2017-12-27
EA201790538A2 (ru) 2017-07-31
CN105381451B (zh) 2021-03-09
IL222739A0 (en) 2012-12-31
SG184907A1 (en) 2012-11-29
JP6526872B2 (ja) 2019-06-05
EA027735B1 (ru) 2017-08-31
EP2563385B1 (en) 2017-08-02
ES2826445T3 (es) 2021-05-18
JP2015187162A (ja) 2015-10-29
NZ603196A (en) 2014-07-25
WO2011139820A1 (en) 2011-11-10
US20130136739A1 (en) 2013-05-30
JP2013527168A (ja) 2013-06-27
PT2563385T (pt) 2017-11-10
EP3260128B1 (en) 2020-07-29
JP5899206B2 (ja) 2016-04-06
US8808697B2 (en) 2014-08-19
NO2563385T3 (https=) 2017-12-30
PT3260128T (pt) 2020-10-22
WO2011139820A8 (en) 2013-02-07
DK2563385T3 (da) 2017-11-06
HK1176007A1 (zh) 2013-07-19
CN102869369A (zh) 2013-01-09
JP2019151655A (ja) 2019-09-12
AU2011248540B2 (en) 2014-11-20
PL3260128T3 (pl) 2021-02-08
EP3845238A1 (en) 2021-07-07
EA201790538A3 (ru) 2017-11-30

Similar Documents

Publication Publication Date Title
CN102869369B (zh) 利用可溶性cd24治疗类风湿性关节炎的方法
US10793617B2 (en) Methods of use of soluble CD24 for therapy of rheumatoid arthritis
AU2011248540A1 (en) Methods of use of soluble CD24 for therapy of rheumatoid arthritis
AU2019204448B2 (en) UTI fusion proteins
EP3601363B1 (en) Alt-803 in combination with anti-cd38 antibody for cancer therapies
WO2015171863A1 (en) USING B-CELL-TARGETING ANTIGEN IgG FUSION AS TOLEROGENIC PROTEIN THERAPY FOR TREATING ADVERSE IMMUNE RESPONSES
KR20200034958A (ko) 암 요법에서 면역 관련된 유해 사례를 치료하기 위한 가용성 cd24의 사용 방법
HK1222554B (zh) 利用可溶性cd24治疗类风湿性关节炎的方法
HK1176007B (en) Methods of use of soluble cd24 for therapy of rheumatoid arthritis
HK40024980A (en) Methods of use of soluble cd24 for treating immune related adverse events in cancer therapies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1176007

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1176007

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160518